权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

NAS-AMP

基本信息

批准号：
600300
负责人：
金额：
$ 29.74万
依托单位：
SISAF LTD
依托单位国家：
英国
项目类别：
EU-Funded
财政年份：
2016
资助国家：
英国
起止时间：
2016 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=600300
关键词：
NAS AMP

项目摘要

The antimicrobial resistance-related costs to the global health care system are estimated at >10 billion Euro peryear. The economic impact is expected to exponentially rise if antimicrobial resistance is not tackled. Infections with MRSA in hospitals, and in particularly Intensive Care Units (ICU) settings, are very serious in terms of the patient’s health, risk of spreading to other patients and the costs of managing and eliminating the infection. The aim of this project is to develop a nasal therapy with antimicrobial peptides (AMPs) to eradicate MRSA carriage. The synthetic AMPs that were previously developed by Madam Therapeutics (Madam) and Leiden University Medical Center (LUMC) have shown to be fully effective against antibiotic-resistant bacterial strains. In collaboration with Madam and LUMC, SiSaf Ltd in Northern Ireland will undertake specialist nanoparticle drug formulation with its patented technology platform for the active AMPs in the project and will include collaboration with the University of Liverpool in relation to microbiology studies and ToxiCoop Pharmacology services in Hungary. The project title is “Development of a novel nasal therapy containing antimicrobial peptides to treat MRSA carriage” and it is funded under the EU EUROSTARS programme for academic and industrial research collaboration. EUROSTARS is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 34 Eurostars Participating States and Partner Countries and by the European Union through Horizon 2020. The UK partner funding is through Innovate UK.

全球卫生保健系统每年与抗菌素耐药性相关的费用估计为100亿欧元。如果不解决抗菌素耐药性问题，预计经济影响将呈指数级上升。在医院，特别是在重症监护病房（ICU）环境中，MRSA感染对患者的健康、传播给其他患者的风险以及管理和消除感染的成本都是非常严重的。该项目的目的是开发一种使用抗菌肽（amp）的鼻腔疗法来根除MRSA携带。以前由Madam Therapeutics （Madam）和莱顿大学医学中心（LUMC）开发的合成amp已被证明对抗生素耐药菌株完全有效。北爱尔兰的SiSaf有限公司将与夫人和LUMC合作，利用其专利技术平台为项目中的活性amp提供专业的纳米颗粒药物配方，并将与利物浦大学合作，在匈牙利进行微生物研究和毒理学服务。该项目名为“开发一种含有抗菌肽的新型鼻疗法来治疗MRSA携带”，由欧盟EUROSTARS计划资助，用于学术和工业研究合作。“欧洲之星”是尤里卡和欧盟委员会的联合项目，由34个“欧洲之星”参与国和伙伴国的国家预算以及欧盟通过“地平线2020”共同资助。英国合作伙伴的资金来自Innovate UK。